Bifidobacterium strain for the prevention and/or treatment of diseases that are with intestinal and hepatic inflammation

The Institute of Agrochemistry and Food Technology (IATA-CSIC), FISABIO, CIBER and the Miguel Hernández University of Elche has identified a new species of bacteria (*Bifidobacterium longum*) that is useful for the prevention and/or treatment of diseases that study with intestinal and hepatic inflammation, as well as pathologies derived from them, such as, for example, liver cirrhosis.

Companies interested in the patent license are being sought for use and development within the field of pharmaceutical preparations, as well as within the field of food.

*An offer for Patent Licensing*

**New strategy to treat or prevent inflammation**

In recent years, the use of a wide range of probiotic strains has been extended, since there is evidence of their contribution in the restoration of alterations in intestinal permeability, intestinal microbial composition and inflammatory response. This concrete strain could be used as a preventive and therapeutic strategy for intestinal or liver inflammatory diseases.

There are results at the in vitro and in vivo level that this bifidobacterium timber strain acts by reducing the levels of pro-inflammatory cytokines (mainly TNF-α, IL-6 and MCP-1) at the intestinal and liver level.

**Main innovations and advantages**

- Probiotic bacteria considered as Generally collected as safe (GRAS)
- Results in the regulation of the inflammatory response in animal models.
- Production of probiotic, nutraceutical formulations, oral administration medications.
- Design of nutritional compositions or nutritional supplements.

**Patent Status**

Spanish patent granted

**For more information, please contact:**

Josep Calaforra Guzman

Instituto de Agroquímica y Tecnología de Alimentos

Spanish National Research Council (CSIC)

Tel.: 96 390 00 22

Email: jcguzman@iata.csic.es

comercializacion@csic.es